3billion Selected for Philippine Government-Led Newborn Genomic Diagnostics Project

• Selected for a newborn genomic diagnostics project led by the Institute of Human Genetics at UP Manila
• To provide WES-based confirmatory testing for newborns with abnormal screening results
• Plans to expand 3B-NEO across high-birth-rate markets in Southeast Asia and Latin America

SEOUL, South Korea, June 11, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it has been selected to provide genomic diagnostic services for a newborn screening project led by the Institute of Human Genetics (IHG) of the National Institutes of Health at the University of the Philippines Manila.

The project will provide whole-exome sequencing (WES)-based confirmatory testing for newborns with abnormal results from the Philippine government’s Expanded Newborn Screening Program. 3billion was selected as the final service provider through a government procurement process and will deliver genomic analysis and diagnostic services for newborns in the Philippines over the next year.

The Philippine government currently screens newborns for approximately 30 congenital and inherited conditions through the Expanded Newborn Screening Program. This project is a pilot initiative for the introduction of genomic newborn screening (gNBS). It aims to evaluate the clinical utility of genomic diagnosis in newborns suspected of having genetic disorders and, over the longer term, expand screening to healthy newborns.

3billion will provide reports containing analyses of disease-associated variants and clinical interpretation to support the confirmatory diagnosis of various genetic conditions, including fatty acid oxidation disorders, galactosemia, biotinidase deficiency, and cystic fibrosis.

The collaboration represents an initial step toward integrating genomic diagnostics into the Philippines’ newborn screening system. It is expected to enable more precise diagnoses and timely access to appropriate treatment while helping lay the foundation for the nationwide adoption of gNBS over the long term.

The contract also marks the first government-led project secured for 3B-NEO, 3billion’s genomic newborn screening service launched earlier this month. Building on this project, the company plans to expand its experience in national newborn genomic diagnostics initiatives and strengthen its capabilities in public healthcare. It will also accelerate its expansion into the global gNBS market, focusing on high-birth-rate regions such as Southeast Asia and Latin America.

“This project goes beyond providing testing services; it marks an early-stage collaboration to integrate genomic diagnostics into the Philippines’ newborn screening system,” said Changwon Keum, CEO of 3billion. “We look forward to supporting the nationwide adoption of gNBS and broader access to precision medicine.”

3billion recently launched Family Insight Test, a family-based precision genomic testing service, and 3B-NEO, a genomic newborn screening service. With these services, the company is expanding beyond rare disease diagnosis into preventive precision medicine for healthy newborns and families.